Anjan Aralihalli | Founder
Raya Therapeutic, Inc.
Anjan founded Raya Therapeutic in 2019. Raya is focused on developing 5 clinical stage NCEs to treat ALS and potentially other neurodegenerative diseases. Prior to Raya, Anjan worked at a variety of biotechs and pharma companies and is a venture partner at CTI Life Sciences Fund 2 (Canada). He has 25+ years of international experience across several functions including investor relations, corporate development, venture and angel financing, in & out-licensing, sales, marketing, & clinical trial management. He continues to provide strategic advice to various biotech companies. Based in the Princeton, New Jersey area, he received his BSc from Concordia University, MBA from Queen's University and MSc in Biotechnology from Johns Hopkins University. Anjan is a corporate fundraiser for Wings Over Wall Street, a NYC based ALS charity and is a member of the board of directors of the Muscular Dystrophy Association (MDA) in the United States.
Appearances:
Day 2 - Wednesday 29 October @ 13:45
Panel: Drug Repositioning – How to get shelved assets that have value for the Orphan drug value chain
We are pleased to confirm the proposed session topics for our Drug Repositioning segment. These include:
Assets (Shelved Assets) – exploring how previously shelved drug candidates can be repurposed for rare diseases.
Success Story (Gomekli) – highlighting the case of Gomekli (mirdametinib) as a successful drug repositioning story.
Accelerator (European Drug Discovery Engine by CTF Europe) – introducing CTF Europe’s new orphan drug discovery engine accelerator initiative.
Investors – discussing how public and private entities can support drug repositioning, and the business rationale behind their involvement.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events